Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of “Moderate Buy” by Brokerages

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has earned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $30.00.

Several analysts have recently commented on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Wall Street Zen downgraded shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright upped their price objective on shares of Kyverna Therapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a report on Friday, May 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Friday, March 27th.

Institutional Trading of Kyverna Therapeutics

Hedge funds have recently modified their holdings of the stock. Public Employees Retirement System of Ohio purchased a new stake in shares of Kyverna Therapeutics in the third quarter worth about $28,000. Qube Research & Technologies Ltd purchased a new stake in Kyverna Therapeutics during the second quarter worth $43,000. Rhumbline Advisers boosted its holdings in Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after buying an additional 5,694 shares in the last quarter. Ameriprise Financial Inc. purchased a new stake in Kyverna Therapeutics during the third quarter worth $77,000. Finally, Bank of America Corp DE boosted its holdings in Kyverna Therapeutics by 41.6% during the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after buying an additional 6,400 shares in the last quarter. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Stock Down 1.5%

Kyverna Therapeutics stock opened at $8.52 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 8.15 and a current ratio of 8.15. The business’s 50-day simple moving average is $9.03 and its two-hundred day simple moving average is $8.50. The company has a market cap of $517.93 million, a PE ratio of -2.60 and a beta of 2.05. Kyverna Therapeutics has a fifty-two week low of $2.47 and a fifty-two week high of $13.67.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.09. Equities analysts anticipate that Kyverna Therapeutics will post -2.81 EPS for the current year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.